Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
Amy C Peterson sold 72,776 shares of EXEL on 16 May at $45.47 per share, worth a total of $3.3M. They now own 465,393 EXEL shares, or a 14% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
